title: A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy.
abstract: The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.
authors.affiliation: Department of Chemistry, BK21 Program, Polymer Research Institute, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.
authors.forename: J
authors.initials: J
authors.lastname: Park
authors.forename: K
authors.initials: K
authors.lastname: Singha
authors.forename: S
authors.initials: S
authors.lastname: Son
authors.forename: J
authors.initials: J
authors.lastname: Kim
authors.forename: R
authors.initials: R
authors.lastname: Namgung
authors.forename: C-O
authors.initials: CO
authors.lastname: Yun
authors.forename: W J
authors.initials: WJ
authors.lastname: Kim
mesh_terms: D000595:Amino Acid Sequence; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D004727:Endothelium / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D016023:Integrins / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000628:therapy*; D009842:Oligopeptides / Q000008:administration & dosage* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D016023:Integrins; D009842:Oligopeptides; C507107:PEI-g-PEG-RGD; D010456:Peptides, Cyclic; D011092:Polyethylene Glycols; C047981:arginyl-glycyl-aspartic acid